Keros Therapeutics, Inc.
NGM: KROSLive Quote
About Keros Therapeutics, Inc.
Healthcare
Biotechnology
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
📊 Fundamental Analysis
Keros Therapeutics, Inc. demonstrates exceptional profitability, with a profit margin of 35.7%.
The company recently reported -87.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is 19.9%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $11.21, KROS currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $10.41 - $22.55).
💰 Valuation Insight
KROS trades at a 80.5% discount (PE: 4.87), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
⚠️
Return on Equity
Moderate
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$199.30M
Trailing P/E
4.87
Forward P/E
-2.22
Beta (5Y)
0.99
52W High
$22.55
52W Low
$10.41
Avg Volume
411K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App